Navellier & Associates Inc. Makes New Investment in Eton Pharmaceuticals, Inc. $ETON

Navellier & Associates Inc. acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 18,010 shares of the company's stock, valued at approximately $652,000. Navellier & Associates Inc. owned 0.07% of Eton Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ETON. Quarry LP acquired a new position in shares of Eton Pharmaceuticals in the 3rd quarter valued at $37,000. Persistent Asset Partners Ltd acquired a new stake in Eton Pharmaceuticals in the 2nd quarter valued at $90,000. Caitong International Asset Management Co. Ltd bought a new stake in Eton Pharmaceuticals in the fourth quarter valued at $44,000. Legal & General Group Plc acquired a new position in Eton Pharmaceuticals during the second quarter worth $41,000. Finally, State of Wyoming bought a new position in Eton Pharmaceuticals during the 2nd quarter valued at about $107,000. 27.86% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ETON has been the subject of a number of recent analyst reports. Canaccord Genuity Group raised their price target on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a "buy" rating in a report on Friday, August 14th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 13th. HC Wainwright increased their price objective on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a "buy" rating in a report on Friday, August 14th. B. Riley Financial reaffirmed a "buy" rating and issued a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $67.50.

Eton Pharmaceuticals Stock Down 4.6%

NASDAQ:ETON opened at $59.78 on Friday. Eton Pharmaceuticals, Inc. has a 12-month low of $14.27 and a 12-month high of $66.37. The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $1.71 billion, a P/E ratio of 157.32 and a beta of 0.86. The stock's fifty day simple moving average is $45.17 and its 200-day simple moving average is $31.90.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.24. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%.The business had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. Equities research analysts expect that Eton Pharmaceuticals, Inc. will post 1.13 earnings per share for the current year.

Insider Buying and Selling

In other Eton Pharmaceuticals news, Director Paul V. Maier sold 50,000 shares of Eton Pharmaceuticals stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the transaction, the director directly owned 59,745 shares in the company, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David Krempa sold 25,000 shares of Eton Pharmaceuticals stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $65.07, for a total value of $1,626,750.00. Following the transaction, the insider owned 37,025 shares in the company, valued at approximately $2,409,216.75. This represents a 40.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 125,000 shares of company stock valued at $6,204,250. 16.49% of the stock is owned by company insiders.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source